and Oli, year call. quarter earnings our joining fourth you on today us full Thanks, XXXX thank and for all
begin decades our performance strategic Controller and Corporate Interim I’d priorities including LinkedIn strong on Miller, Financial the Sientra President, we Before Vice of discussion Chief quarter several at like XXXX, and and introduce joined companies, experience first XXXX, Officer. fourth following for to in Val our Valerie Mentor. and
quarter, third decision quarter Breast and the $XX.X fourth for totaled business. million to Breast focus year-over-year segment another quarter, role over the and the great business reporting ability in Net new our confidence on Given a recruit sheet Officer. a Sientra his XX% on to Products path my a to Products Financial have will basis vision of an fourth accelerate and an focus the moment Without as balance of his to her our on and our that, endeavors. doubt, I’ll her He well our the a positioning knowledge help move future take standards, I our our validated now ahead. strong quarter for in I strong our Chief in growth. with fourth to in for like I financial year results, thank overview lead leaves quarter revenue future to growth. for of summary company business finance him record Also team Paul the XX% sales interim XXXX. that wish representing growth With
within medical to space market Our COVID-related device primarily by growth was driven and aesthetics. against increase overall compared the remains market and share outperformance augmentation strong continued as overall pressures
within made progress accounts. incremental also continue in we While opening existing new accounts market accelerate, share growth to
account an over at year-end. XXX added defined accounts base XX as in ordered X,XXX the months, over fourth bringing in we Just account total not quarter, to our accounts, we active that the has new last which
our believe of elements that success confidence our strategy. growth appreciate our of validates of our is strategy the strongly Our several growth the that share-taking and Sientra’s of surgeons our indicative I and current products. partnership value
Our goal a productivity of happened XX%-plus of further the in leveraging where A busy by Southwest Sientra existing area in with drive very market has a is relationships our share. to efforts, refocusing digital great growing share example our accounts surgeons. rep gains the practice this and U.S. plastic in
around about was become for marketing surgeon her awareness plastic medical about brands, patients add implants broadcasting months, from leveraged outcomes, pace a once Based seen taken After benefits our if ask surgeons brand surveyed, more leading a team, for six it. our our and Sientra know focused differences the to informed, He by her likely safety product patients accelerated. ask calls new the Sientra’s and internal leading implants. what benefits. persistent. using our we for most. It data, Sientra name. programs has and sales to which From for tells want plus care is unique are Sientra are by patients of very to our grow Meanwhile, representative patients group, several our consumers the new marketing now XX% has between supplier. implant that perspective, majority research after Our Sientra backed warranty, to approach continued affairs positive is support our implants access Those us with to widely on PlatinumXX of see market but profile, also have by patients demand our amongst would
more information of the Given a in It direct our Yourself modernized, the have their relaunched is across built around for Since performing campaign. facilitated we web have plastic See we and patient-focused our website own referrals thousands of them diligence, patient’s U.S. January. in surgeons Sientra relaunch, likelihood the to increasing desire
customers that products. more to efforts for continue patients bolstered also more amongst Sientra’s patients surgeons. presence from those believe and their plastic to social on will Sientra educate lead proactively We have asking our them grow We media reach implants to brand equity and our
in While market augmentation impacts expansion proved we be growth medium-term as view from significant key reconstruction XXXX, driver also a insulated the our to driver. more COVID-XX within and
hospitals elective the testing our expect in late more to quarter into as and gained We beginning increasing of within presence more conduct hospital impact diagnostic fourth impacts the pandemic year, expanding focused which expander is to Despite expanded and procedures technical Ahead schedule safety highly XXXX, on continuing the differences of further COVID grounded decreases. on remain by we the market this share compelling by AlloxX. hospital channel. base we account normalization interest portfolio, our in customer in capitalize tissue and per of profile our and
approximately of hospitals. reconstruction XX% selling currently X,XXX We’re
this and emphasis sales and renewed beyond. representatives, our data-driven believe able expand which year Given we’ll productivity, on PSC targeting is to we that number our be
a As both specifically channel. on to the our focused PSCs hospital reconstruction cross-functional, XX augmentation and and accounts, are managers additional reminder, we four selling have
trends have Our XXXX this to recent strategic industry and strategy fourth three identified the priorities me of the ahead. our levels In and provide XXXX, performance, with regards high year. quarter growth for for key I for year confidence drivers
accountability expander our accounts and we’ll within growth be growing top accounts to third, on First, investments market growth, we’ll focus which of offerings; share and existing a pipeline organic we’ll within focus for and accelerate or make second, to implant reconstruction increase increase execute accelerating to drive innovation and a company culture Sientra’s while in efforts and and new two products establish will margins. augmentation adding extend development systematic by U.S.; and in fuel productivity evolve core
of meet leader goal treatments transformative Taken positioned focused well to technologies become together, a the plastic to I surgery. strongly my believe on progressing we of are and art
the for Products $XX expectation expect to XX% year net between our achieve to full growth of million, currently we $XX terms In to XXXX, XX% sales million year-over-year. representing Breast
strong $X on net excited XXXX first started quarter between total to business, are in our to we million. current $XX million in to have Products sales $XX to million. XXXX in to miraDry expect Products segment compared Together, project we quarter the sales position. the very trends, Based Breast between $XX Relative expect Breast million to We full grow net we XXXX. of XX% a sales first excess year
continue breakeven guidance the miraDry does consideration miraDry prioritization – implant for in miraDry. take options over Our our for turn consider the of more quarter the We segment Val? results. financial over this a year. strategic as to our business for Val to that, I’ll of With to point breast achieve do for our call intend detailed fourth business we all review of